Switch theme
Sign up to access all valuation multiples
Jiangxi Fushine Pharmaceutical Co Ltd is engaged in research and development, manufactures and sells APIs and pharmaceutical intermediates. It offers penicillin, carbapenem, and other products.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiangxi Fushine Pharma Co has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Jiangxi Fushine Pharma Co achieved revenue of $222M and an EBITDA of -$4.4M.
Jiangxi Fushine Pharma Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangxi Fushine Pharma Co valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $222M | n/a | XXX | XXX | XXX |
| Gross Profit | $60.1M | $40.9M | XXX | XXX | XXX |
| Gross Margin | 27% | NaN% | XXX | XXX | XXX |
| EBITDA | -$4.4M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2% | NaN% | XXX | XXX | XXX |
| Net Profit | $6.7M | -$19.5M | XXX | XXX | XXX |
| Net Margin | 3% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | $59.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Jiangxi Fushine Pharma Co's stock price is CNY 8 (or $1).
Jiangxi Fushine Pharma Co has current market cap of CNY 4.5B (or $618M), and EV of CNY 5.4B (or $748M).
See Jiangxi Fushine Pharma Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $748M | $618M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Jiangxi Fushine Pharma Co has market cap of $618M and EV of $748M.
Jiangxi Fushine Pharma Co's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Jiangxi Fushine Pharma Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jiangxi Fushine Pharma Co and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $748M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJiangxi Fushine Pharma Co's NTM/LTM revenue growth is n/a
Jiangxi Fushine Pharma Co's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Jiangxi Fushine Pharma Co's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jiangxi Fushine Pharma Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jiangxi Fushine Pharma Co and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 19% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Actuate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangxi Fushine Pharma Co acquired XXX companies to date.
Last acquisition by Jiangxi Fushine Pharma Co was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangxi Fushine Pharma Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jiangxi Fushine Pharma Co founded? | Jiangxi Fushine Pharma Co was founded in 2002. |
| Where is Jiangxi Fushine Pharma Co headquartered? | Jiangxi Fushine Pharma Co is headquartered in China. |
| Is Jiangxi Fushine Pharma Co publicy listed? | Yes, Jiangxi Fushine Pharma Co is a public company listed on SHE. |
| What is the stock symbol of Jiangxi Fushine Pharma Co? | Jiangxi Fushine Pharma Co trades under 300497 ticker. |
| When did Jiangxi Fushine Pharma Co go public? | Jiangxi Fushine Pharma Co went public in 2015. |
| Who are competitors of Jiangxi Fushine Pharma Co? | Similar companies to Jiangxi Fushine Pharma Co include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Jiangxi Fushine Pharma Co? | Jiangxi Fushine Pharma Co's current market cap is $618M |
| Is Jiangxi Fushine Pharma Co profitable? | Yes, Jiangxi Fushine Pharma Co is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
